Eli Lilly (LLY) Stock Analysis
NYQ · Healthcare · Drug Manufacturers - General
$1189.17
+5.71 (+0.48%)
LLY Interactive Price Chart & Trading Signals
LLY Stock Snapshot — Valuation, Risk & Technical Signals
LLY Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$1060.43B
P/E Ratio
39.88
Forward P/E
25.12
PEG Ratio
1.17
P/B Ratio
31.29
EPS
$29.82
Dividend Yield
0.58%
52W Range
$716.08 – $1292.65
Beta
0.50
Volume
0.5M
ROE
102.3%
Profit Margin
33.5%
Revenue Growth
47.7%
Gross Margin
83.4%
EV/EBITDA
26.39
Analyst Target
$1328.83
The trailing price-to-earnings ratio stands at 39.9x. Forward P/E of 25.1x implies earnings expansion expected. Price-to-book is 31.29x. EV/EBITDA sits at 26.39x. Market capitalization is $1.06T. Revenue is growing at 47.7% on a trailing basis. Earnings are expanding at 26.2%. Profit margins are 33.5%. Return on equity is 102.3%. Beta of 0.50 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$930.00
Mean Target
$1328.83
High Target
$1600.00
Based on 29 analysts
About Eli Lilly
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
Growth-oriented investorsWatch out for
Premium valuationNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Eli Lilly and Company (LLY) trades above our multi-model fair value estimate of $326.29 by approximately 72.6%. Trailing P/E: 39.9x. Profitability signals include profit margin of 33.5% and return on equity of 102.3%. Recent growth metrics show revenue growth of 47.7% and earnings growth of 26.2%. Risk profile: defensive beta of 0.50. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 39.9x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 47.7%
Revenue is outpacing the market.
Risk
Low
Beta 0.50
Movement is likely to track the broader market.
Valuation Snapshot
Eli Lilly and Company (LLY) trades above our multi-model fair value estimate of $326.29 by approximately 72.6%. The trailing price-to-earnings ratio stands at 39.9x. Forward P/E of 25.1x suggests earnings compression ahead. Price-to-sales is 13.3x. Price-to-book is 31.3x. EV/EBITDA sits at 26.4x. Market capitalization is $1.06T.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 47.7% on a trailing basis. Earnings are expanding at 26.2%. Profit margins are 33.5%. Return on equity is 102.3%. Return on assets is 20.4%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.50 indicates defensive profile. Net debt position is $45.96B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $1328.83 implies 11.7% upside. Target range spans $930.00 to $1600.00. 29 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Premium valuation is supported by above-average growth, potentially fitting growth-oriented strategies.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
LLY Overvalued
Eli Lilly and Company (LLY) trades above our multi-model fair value estimate of $326.29 by approximately 72.6%.
Frequently Asked Questions
ValuationIs LLY stock overvalued right now?
ValuationWhat is LLY fair value based on current fundamentals?
RiskHow risky is LLY compared with other stocks?
GrowthIs LLY still growing?
AnalystWhat do analysts think about LLY?
DividendDoes LLY pay a dividend?
CatalystWhat could change the investment case for LLY?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.